Can-Fite says liver cancer patient from Phase II Namodenoson trial hits ten-year survival

Can-Fite BioPharma Ltd. announced on November 9, 2026 that a patient with advanced liver cancer who took part in its completed Phase II study of Namodenoson has now reached ten years of overall survival.¹ The company said the patient, whose complete response had been reported previously, continues to be cancer-free and healthy.¹

Can-Fite described the result as notable given the disease involved, noting that reaching a decade of survival is an exceptional individual outcome in advanced hepatocellular carcinoma, the most common type of liver cancer.¹ This update follows an earlier milestone report, since the company had announced nine-year survival for the same patient in November 2025.¹

Prof. Pnina Fishman, Can-Fite's Chairperson and Chief Scientific Officer, commented on the patient's story and said the outcome reinforces the company's resolve to continue developing Namodenoson, calling it a deeply meaningful achievement for patients, families, and those working on new treatments, and saying it strengthens the company's commitment to advancing Namodenoson toward durable clinical benefit for liver cancer patients.¹

The Phase II result comes as Namodenoson is being tested in a separate, ongoing Phase III trial. That trial is a randomized, double-blind, placebo-controlled pivotal study enrolling HCC patients with Child-Pugh B7 cirrhosis, as described in the filing. On September 2, 2026, Can-Fite had disclosed that overall survival across the blinded, pooled trial population looked longer than the study's design had assumed, which led the company to consider moving up the timing of its planned interim analysis. The filing noted that the trial remains blinded, so the survival signal reflects both Namodenoson and placebo patients combined, and that any drug-specific efficacy conclusions will wait for the planned interim analysis.

The release also noted that Namodenoson carries Orphan Drug Designation in the U.S. and Europe and Fast Track Designation from the FDA as a second-line HCC treatment.¹